CD33 and acute myeloid leukemia: To improve the CD33 | CD16b construct and address matters that include relapse from single-antigen-loss in AML, blood cancers beyond AML, and protection of HSCs, we created proof-of-concept Tmod designs that incorporate 2 additional antigen-binding domains directed at SPN and CLEC9A placed in tandem with the CD33 scFv for the SPN activator and the CD16b scFv for the CLEC9A blocker.